Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
53.14 USD | +2.83% | +2.41% | -15.32% |
24/04 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
23/04 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.32% | 11.6B | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-13.56% | 15.36B | |
-8.82% | 11.95B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B | |
+2.34% | 7.72B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte : Earnings Flash (INCY) INCYTE Reports Q1 EPS $0.67, vs. Street Est of $0.64